{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:16:00Z","timestamp":1792804560142,"version":"4.5.0"},"reference-count":131,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Merz Pharma GmbH","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p> Sialorrhoea is a frequent symptom of neurological diseases (e.g. Parkinson\u2019s disease, motor neuron disease, cerebral palsy, and stroke) and is defined as excessive saliva accumulation leading to unintentional loss of saliva from the mouth. Sialorrhoea increases the overall burden on the patient and their caregivers, the impact of which can be both physical and psychosocial. Treatments for sialorrhoea range from lifestyle and behavioural guidance, to medications, surgery or radiation. Nonpharmacological interventions include advice on posture, swallowing control, cough management, dietary changes, eating and drinking techniques, and behavioural modification; however, these conservative measures may be ineffective for people with progressive neurological conditions. The pharmacological treatment of sialorrhoea is challenging because medications licensed for this purpose are limited, but treatments can include anticholinergic drugs and botulinum toxins. Surgical treatment of sialorrhoea is typically reserved as a last resort for patients. IncobotulinumtoxinA (Xeomin\u00ae) is the first botulinum toxin type A to receive US and UK marketing authorization for the symptomatic treatment of chronic sialorrhoea due to neurological disorders in adults. In this review, we discuss and compare the frequency and method of administration, location of treatment delivery, approximate annual costs and main side effects of botulinum toxin and different anticholinergic drugs. Management of patients with chronic neurological conditions requires input from multiple specialist teams and thus a multidisciplinary team (MDT) approach is considered fundamental to ensure that care is consistent and tailored to patients\u2019 needs. To ensure that adult patients with neurological conditions receive the best care and sialorrhoea is well managed, we suggest a potential clinical care pathway for sialorrhoea with a MDT approach, which healthcare professionals could aspire to. <\/jats:p>","DOI":"10.1177\/1756286419888601","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T13:29:58Z","timestamp":1574947798000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":55,"title":["The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin\u00ae)"],"prefix":"10.1177","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9834-3639","authenticated-orcid":false,"given":"Francesca","family":"Morgante","sequence":"first","affiliation":[{"name":"Neurosciences Research Centre, Molecular and Clinical Sciences Research Institute, St George\u2019s University of London, London, United Kingdom; Department of Experimental and Clinical Medicine, University of Messina"},{"name":"Molecular and Clinical Sciences Research Institute, St George\u2019s University of London, London, United Kingdom Cranmer Terrace, Jenner Wing, Ground Floor, Corridor 10, Room 0.135, London, SW17 0RE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Bavikatte","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, The Walton Centre NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahim","family":"Anwar","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Cambridge University Hospital NHS Foundation Trust, Addenbrooke\u2019s Hospital, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biju","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Department of Medicine and Gerontology, University Hospital of Wales, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,11,28]]},"reference":[{"key":"bibr1-1756286419888601","first-page":"25","volume":"5","author":"Bavikatte G","year":"2012","journal-title":"Br J Med Pract"},{"key":"bibr2-1756286419888601","doi-asserted-by":"publisher","DOI":"10.3390\/toxins5051010"},{"key":"bibr3-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2016-001515"},{"key":"bibr4-1756286419888601","doi-asserted-by":"publisher","DOI":"10.2165\/0002512-200825120-00003"},{"key":"bibr5-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-5098-2"},{"key":"bibr6-1756286419888601","first-page":"2628","volume":"69","author":"Hockstein NG","year":"2004","journal-title":"Am Fam Physician"},{"key":"bibr7-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmr.2008.07.001"},{"key":"bibr8-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-2457(03)00237-2"},{"key":"bibr9-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-011-1570-y"},{"key":"bibr10-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199684243.003.0021"},{"key":"bibr11-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1177\/000348940811700209"},{"key":"bibr12-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1016\/j.tripleo.2005.08.018"},{"key":"bibr13-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2011.03501.x"},{"key":"bibr14-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-208919"},{"key":"bibr15-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-016-0297-y"},{"key":"bibr16-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1080\/17482960701656940"},{"key":"bibr17-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000208957.88534.11"},{"key":"bibr18-1756286419888601","doi-asserted-by":"publisher","DOI":"10.3109\/21678421.2013.855790"},{"key":"bibr19-1756286419888601","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.02103"},{"key":"bibr20-1756286419888601","doi-asserted-by":"publisher","DOI":"10.3109\/21678421.2013.790452"},{"key":"bibr21-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000233840.41688.df"},{"key":"bibr22-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22643"},{"key":"bibr23-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23462"},{"key":"bibr24-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12454"},{"key":"bibr25-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12893"},{"key":"bibr26-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.12.004"},{"key":"bibr27-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23720"},{"key":"bibr28-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2007.12.007"},{"key":"bibr29-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2009.12.003"},{"key":"bibr30-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afl105"},{"key":"bibr31-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.11100315"},{"key":"bibr32-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1017\/S001216220500112X"},{"key":"bibr33-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2009.03428.x"},{"key":"bibr34-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2010.03765.x"},{"key":"bibr35-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1007\/BF01383388"},{"key":"bibr36-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1007\/BF00341262"},{"key":"bibr37-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1080\/13668250903074489"},{"key":"bibr38-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1111\/jocn.13922"},{"key":"bibr39-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1159\/000016094"},{"key":"bibr40-1756286419888601","first-page":"825","volume":"86","author":"Kidd D","year":"1993","journal-title":"Q J Med"},{"key":"bibr41-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-9993(98)90200-3"},{"key":"bibr42-1756286419888601","doi-asserted-by":"publisher","DOI":"10.5535\/arm.2013.37.1.96"},{"key":"bibr43-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1097\/00001199-199910000-00005"},{"key":"bibr44-1756286419888601","unstructured":"National Health Service trusts and National Health Service foundation trusts. National schedule of reference costs: year 2017\u20132018, https:\/\/improvement.nhs.uk\/resources\/reference-costs\/#rc1718 (2018, accessed 20 January 2019)."},{"key":"bibr45-1756286419888601","unstructured":"Owen S. Hypersalivation \u2013 what drug treatment options are available? https:\/\/www.sps.nhs.uk\/articles\/hypersalivation-d-what-drug-treatment-options-are-available\/ (2015, accessed 26 November 2018)."},{"key":"bibr46-1756286419888601","unstructured":"National Institute of Health and Clinical Excellence. Parkinson\u2019s disease in adults, https:\/\/www.nice.org.uk\/guidance\/ng71 (2017, 26 November 2018)."},{"key":"bibr47-1756286419888601","unstructured":"National Institute of Health and Clinical Excellence. Motor neurone disease: assessment and management, https:\/\/www.nice.org.uk\/guidance\/NG42 (2016, 26 November 2018)."},{"key":"bibr48-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27602"},{"key":"bibr49-1756286419888601","volume":"73","author":"Miller RG","year":"1227","journal-title":"Neurology"},{"key":"bibr50-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.74.9.1258"},{"key":"bibr51-1756286419888601","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S40783"},{"key":"bibr52-1756286419888601","unstructured":"Hanratty A, Husbands E, Kelly F, et al. Managing saliva problems in motor neurone disease: information for health and social care professionals: MNDA, Motor Neurone Disease Association. Version 1.1. https:\/\/static.mndassociation.org\/app\/uploads\/2012\/04\/19135720\/information-sheet-p3-managing-saliva-problems.pdf (2017, accessed 09 November 2019)."},{"key":"bibr53-1756286419888601","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.02856"},{"key":"bibr54-1756286419888601","doi-asserted-by":"crossref","first-page":"107","DOI":"10.33590\/emjneurol\/10312710","volume":"3","author":"Pellegrini A","year":"2015","journal-title":"EMJ Neurology"},{"key":"bibr55-1756286419888601","unstructured":"Bayer plc. Kwells 300 microgram tablets - hyoscine hydrobromide. https:\/\/www.medicines.org.uk\/emc\/files\/pil.250.pdf (2015, accessed 01 May 2019)."},{"key":"bibr56-1756286419888601","unstructured":"Sanofi. Buscopan(R). Ampoules 20 mg\/ml solution for injection. https:\/\/www.medicines.org.uk\/emc\/files\/pil.890.pdf (2017, accessed 01 May 2019)."},{"key":"bibr57-1756286419888601","unstructured":"GlaxoSmithKline. Scopoderm 1.5 mg patches. https:\/\/www.medicines.org.uk\/emc\/files\/pil.3276.pdf (2018, accessed 01 May 2019)."},{"key":"bibr58-1756286419888601","unstructured":"Martindale Pharma. Atropine eye drops 1.0% w\/v. https:\/\/www.medicines.org.uk\/emc\/files\/pil.3297.pdf (2016, accessed 01 May 2019)."},{"key":"bibr59-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1177\/0269216306071702"},{"key":"bibr60-1756286419888601","unstructured":"Martindale Pharma. Glycopyrronium bromide 200 micrograms\/ml solution for injection. https:\/\/www.medicines.org.uk\/emc\/files\/pil.3389.pdf (2018, accessed 01 May 2019)."},{"key":"bibr61-1756286419888601","unstructured":"Merz Pharma. Xeomin summary of product characteristics (United Kingdom), 2019. https:\/\/www.medicines.org.uk\/emc\/product\/4609\/smpc (2019, accessed 10 June 2019)."},{"key":"bibr62-1756286419888601","unstructured":"Merz Pharma. Xeomin full prescribing information (United States). Raleigh, NC: Merz North America, Inc, 2018. https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=ccdc3aae-6e2d-4cd0-a51c-8375bfee9458&type=display (2018, accessed 01 May 2019)."},{"key":"bibr63-1756286419888601","first-page":"516","volume":"14","author":"Stokholm MG","year":"2013","journal-title":"Amyotroph Lat Scl Fr"},{"key":"bibr64-1756286419888601","unstructured":"US WorldMeds. Full Prescribing Information: MYOBLOC (rimabotulinumtoxinB) injection, for intramuscular or intraglandular use. US Food and Drug Administration, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/103846s5190lbl.pdf#page=18 (2019, accessed 01 May 2019)."},{"key":"bibr65-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-0738-5"},{"key":"bibr66-1756286419888601","unstructured":"Eisai Manufacturing Limited. Summary of product characteristics: NeuroBloc. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/neurobloc-epar-product-information_en.pdf. (2001, accessed 01 May 2019)"},{"key":"bibr67-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03659.x"},{"key":"bibr68-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d8c1b7"},{"key":"bibr69-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10276"},{"key":"bibr70-1756286419888601","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S26893"},{"key":"bibr71-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.154.12.1214"},{"key":"bibr72-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1177\/019459989010300415"},{"key":"bibr73-1756286419888601","unstructured":"National Institute of Health and Care Excellence. Final appraisal document: Xeomin (botulinum neurotxin type A) for treating chronic sialorrhoea, 2019. https:\/\/www.nice.org.uk\/guidance\/gid-ta10296\/documents\/final-appraisal-determination-document (2019, accessed 01 September 2019)."},{"key":"bibr74-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03131.x"},{"key":"bibr75-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000101713.81253.4C"},{"key":"bibr76-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10420"},{"key":"bibr77-1756286419888601","doi-asserted-by":"publisher","DOI":"10.3390\/toxins10060217"},{"key":"bibr78-1756286419888601","first-page":"1","volume":"7","author":"Marvulli R","year":"2017","journal-title":"J Alzheimers Dis Parkinsonism"},{"key":"bibr79-1756286419888601","first-page":"173","volume":"5","author":"Kukreja R","year":"2015","journal-title":"Res Rep Biochem"},{"key":"bibr80-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23473"},{"key":"bibr81-1756286419888601","doi-asserted-by":"publisher","DOI":"10.3390\/toxins10020055"},{"key":"bibr82-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2008.11.011"},{"key":"bibr83-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-0085-1"},{"key":"bibr84-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21213"},{"key":"bibr85-1756286419888601","first-page":"7","author":"Mazlan M","year":"2015","journal-title":"Toxins"},{"key":"bibr86-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-018-3279-4"},{"key":"bibr87-1756286419888601","doi-asserted-by":"publisher","DOI":"10.5152\/npa.2015.7477"},{"key":"bibr88-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20545"},{"key":"bibr89-1756286419888601","unstructured":"National Patient Safety Agency, Royal College of Speech and Language Therapists, National Association of Care Catering, et al. Dysphagia diet food texture descriptors. http:\/\/www.hospitalcaterers.org\/media\/1160\/dysphagia-descriptors.pdf (2011, accessed 18 January 2019)."},{"key":"bibr90-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.034702"},{"key":"bibr91-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.8.1059"},{"key":"bibr92-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007368"},{"key":"bibr93-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2016.07.001"},{"key":"bibr94-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-017-1767-y"},{"key":"bibr95-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1002\/pnp.515"},{"key":"bibr96-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2016.1221433"},{"key":"bibr97-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10639"},{"key":"bibr98-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-015-0029-9"},{"key":"bibr99-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bdj.4812740"},{"key":"bibr100-1756286419888601","unstructured":"Aging Brain Program. Anticholinergic cognitive burden scale: 2012 Update: Regenstrief Institute, Inc. 2008. https:\/\/psnc.org.uk\/lancashire-lpc\/wp-content\/uploads\/sites\/97\/2014\/02\/Anticholinergic-burden-scale-2012.pdf (2012, accessed 14 February 2019)."},{"key":"bibr101-1756286419888601","doi-asserted-by":"publisher","DOI":"10.2217\/1745509X.4.3.311"},{"key":"bibr102-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006292126"},{"key":"bibr103-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2007.106"},{"key":"bibr104-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2003.10.012"},{"key":"bibr105-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1016\/j.anorl.2010.12.010"},{"key":"bibr106-1756286419888601","unstructured":"National Institute of Health and Care Excellence. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine, 2012. https:\/\/www.nice.org.uk\/guidance\/ta260\/resources\/botulinum-toxin-typea-for-the-prevention-of-headaches-in-adults-with-chronic-migraine-pdf-82600545273541 (2012, accessed 01 May 2019)."},{"key":"bibr107-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006688"},{"key":"bibr108-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2008.12.007"},{"key":"bibr109-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.69.1.121"},{"key":"bibr110-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1001\/archoto.2009.110"},{"key":"bibr111-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2015.3592"},{"key":"bibr112-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.11.230"},{"key":"bibr113-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2010.0308"},{"key":"bibr114-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1007\/s40136-018-0188-2"},{"key":"bibr115-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5876(02)00281-1"},{"key":"bibr116-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2015.02.008"},{"key":"bibr117-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2273.1997.00022.x"},{"key":"bibr118-1756286419888601","first-page":"126","volume":"51","author":"McAloney N","year":"2005","journal-title":"J Ir Dent Assoc"},{"key":"bibr119-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1097\/00006534-200104010-00001"},{"key":"bibr120-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2005.01351.x"},{"key":"bibr121-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1111\/j.1754-4505.1995.tb00524.x"},{"key":"bibr122-1756286419888601","volume":"128","author":"Stern Y","year":"2002","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"bibr123-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2007.01983.x"},{"key":"bibr124-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2011.06.016"},{"key":"bibr125-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12559"},{"key":"bibr126-1756286419888601","doi-asserted-by":"publisher","DOI":"10.3109\/17482968.2012.690419"},{"key":"bibr127-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000180717.29273.12"},{"key":"bibr128-1756286419888601","doi-asserted-by":"publisher","DOI":"10.21037\/apm.2017.10.01"},{"key":"bibr129-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1080\/17482960802103131"},{"key":"bibr130-1756286419888601","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179796"},{"key":"bibr131-1756286419888601","unstructured":"Pan Mersey Area Prescribing Committee. Pharmacological management of hypersalivation in children and adults. Prescribing Guideline Version 1.2. https:\/\/www.panmerseyapc.nhs.uk\/media\/2066\/hypersalivation.pdf (2017, accessed 30 November 2018)."}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756286419888601","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1756286419888601","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756286419888601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T04:59:06Z","timestamp":1740805146000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1756286419888601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":131,"alternative-id":["10.1177\/1756286419888601"],"URL":"https:\/\/doi.org\/10.1177\/1756286419888601","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"article-number":"1756286419888601"}}